Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportGI

Role of FDG PET based metabolic tumor volume (MTV) in prognostication of locally advanced gallbladder carcinoma

Shantanu Pande, Nihit Mhatre, Zaeba Nayeem and Jyoti Ranjan Swain
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 3021;
Shantanu Pande
1All India Institutes of Medical Sciences, Nagpur
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nihit Mhatre
2Tata Memorial Centre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zaeba Nayeem
2Tata Memorial Centre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jyoti Ranjan Swain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

3021

Introduction: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a noninvasive procedure that allows assessment of glucose metabolism. A semi-quantitative parameter is SUVmax (maximum standardized uptake value) is one of known prognostic parameter; however this indicates only single voxel value and not metabolism of whole. MTV (metabolic tumor volume) is calculated using various thresholds (40% of the tumor SUVmax or SUV cut off of 2.5). Utility of MTV as prognostic marker is proven in esophageal cancer, head and neck cancers. In continuation to this we tried to find correlation of metabolic tumor volume of primary gallbladder carcinoma based on fixed relative threshold (MTV40, i.e. 40% of SUVmax) and fixed absolute threshold method (MTV2.5, i.e. SUV of 2.5) of baseline FDG-PET/CT with the overall survival in cases of locally advanced Gallbladder carcinoma (GBC).

Methods: A total of 32 patients of confirmed GBC who were referred for FDG- PET/CT from September 2018 to May 2020 were included in this retrospective study. The locally advanced GB lesions were defined as T3-T4 GB lesion or inva­sion of adjacent structures or regional nodal metastasis. Cases with distant metastases, insufficient medical records, and patients who have received cancer directed systemic therapy were excluded. PET VCAR (Volume Computer Assisted Reading) software was used to calculate metabolic tumor volume of primary tumor (MTV) based on fixed absolute threshold method (MTV2.5, i.e. SUV of 2.5) and fixed relative threshold (MTV40 i.e. 40 % of SUVmax). All patients were treated with chemotherapy. For evaluation of treatment response was based on follow up CT or PET/CT whichever available. If follow up imaging is not available then clinical records or last follow up visit was considered.

Statistical analysis: -

Overall survival was defined as duration between date of diagnosis to date of death due to any cause or date of last follow up. Kaplan-Meier method was used for the estimation of the probability of Overall survival (OS). Univariate analysis was performed with log-rank test. The maximally selected rank statistics from the 'maxstat' R package was used to determine cut point for variables. All tests were 2 tailed and significance set at p<0.05, the MTV was reported with 95% confidence intervals (CI). Analysis was performed using R version 3.4.2, from the Comprehensive R Archive Network (R Core team, 2020).

Results: In our study, data of 32 patients was analyzed. The average duration of follow up was 5.8 months. ON folow up 12/32 patients died ( average duration of follow up 5 months). 10 patients were detected with disease progression (average duration of follow up 5.5 months). Rest of patients showed response to treatment or stable disease. Cutoff of metabolic tumor volume of primary tumor based on fixed absolute threshold method (MTV2.5) was found to be 272.35 and for fixed relative threshold method (MTV40), it was 67.83. Six (06) months and 1year survival percentage of patients with MTV more than 272 was found to be 54 % & 36 % compared to 87 % & 81 % survival percentage for patients with MTV less than 272 respectively. The MTV2.5 of primary tumor was found to be prognostically significant (p<0.05). The MTV40 of primary tumor did not correlate with overall survival.

Conclusions: In our study, there appears correlation between fixed absolute threshold method based metabolic tumor volume of primary gallbladder tumor (MTV2.5) with the overall survival in cases of locally advanced gallbladder carcinoma. Therefore, MTV2.5 can be used routinely for identifying patients with poor prognosis and further clinical management. For MTV40, further data and analysis is required before any conclusion.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Role of FDG PET based metabolic tumor volume (MTV) in prognostication of locally advanced gallbladder carcinoma
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Role of FDG PET based metabolic tumor volume (MTV) in prognostication of locally advanced gallbladder carcinoma
Shantanu Pande, Nihit Mhatre, Zaeba Nayeem, Jyoti Ranjan Swain
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 3021;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Role of FDG PET based metabolic tumor volume (MTV) in prognostication of locally advanced gallbladder carcinoma
Shantanu Pande, Nihit Mhatre, Zaeba Nayeem, Jyoti Ranjan Swain
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 3021;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Head-to-head comparison between 68Ga-RM26 and 18F-FDG PET/CT in gastrointestinal stromal tumors (GIST): a pilot study
  • Is Novel FAPI-PET Imaging Superior than FDG-PET Imaging for The Surveillance of Anastomotic Recurrence in Postoperative Patients with Gastrointestinal Cancer?
  • Evaluation of advanced hepatocellular carcinoma with 68Ga-PSMA PET/CT, a prospective study!
Show more GI

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire